Literature DB >> 9377477

Ribonucleotide reductase--structural studies of a radical enzyme.

H Eklund1, M Eriksson, U Uhlin, P Nordlund, D Logan.   

Abstract

Ribonucleotide reductase contains a stable organic free radical essential for its activity located on a tyrosine residue in the small subunit of the enzyme called R2. The substrate binding site is, however, found in the catalytic subunit called R1. A long-range protein-mediated radical transfer pathway appears to be responsible for the delivery of the radical from the tyrosine in R2 to the substrate on R1. The active site is located deep inside the protein in a very stable beta/alpha-barrel structure and a hydrogen bonded system leads from the surface to Cys439 at the active site which is in excellent position to remove a hydrogen from the 3' of the ribose of a bound substrate nucleotide.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9377477

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  6 in total

1.  Functional anthology of intrinsic disorder. 3. Ligands, post-translational modifications, and diseases associated with intrinsically disordered proteins.

Authors:  Hongbo Xie; Slobodan Vucetic; Lilia M Iakoucheva; Christopher J Oldfield; A Keith Dunker; Zoran Obradovic; Vladimir N Uversky
Journal:  J Proteome Res       Date:  2007-03-29       Impact factor: 4.466

2.  Vegetative incompatibility in the het-6 region of Neurospora crassa is mediated by two linked genes.

Authors:  M L Smith; O C Micali; S P Hubbard; N Mir-Rashed; D J Jacobson; N L Glass
Journal:  Genetics       Date:  2000-07       Impact factor: 4.562

3.  Glutathione-dependent thioredoxin reduction and lipoamide system support in-vitro mammalian ribonucleotide reductase catalysis: a possible antioxidant redundancy.

Authors:  Ajanta Chatterji; Kumar Sachin; Rajib Sengupta
Journal:  Mol Biol Rep       Date:  2022-06-02       Impact factor: 2.742

Review 4.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

5.  Hole Hopping through Tryptophan in Cytochrome P450.

Authors:  Maraia E Ener; Harry B Gray; Jay R Winkler
Journal:  Biochemistry       Date:  2017-07-09       Impact factor: 3.162

6.  Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy.

Authors:  Sanath R Wijerathna; Md Faiz Ahmad; Hai Xu; James W Fairman; Andrew Zhang; Prem Singh Kaushal; Qun Wan; Jianying Kiser; Chris G Dealwis
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.